SYK-IN-15
SYK-IN-15 is an orally active spleen tyrosine kinase (SYK) inhibitor with an IC50 of 10.9 nM. SYK-IN-15 induces cell cycle S-phase arrest and cell apoptosis. SYK-IN-15 inhibits cancer cell colony formation and exerts antiproliferative effects on cancer cells. SYK-IN-15 can be used for the research of solid tumors (ovarian cancer, breast cancer, liver cancer).
For research use only. We do not sell to patients.
- Formula: C28H35N9O
- Molecular Weight:513.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
SYK-IN-15 (Compound B13) (1-10 μM; 24 h) exerts potent antiproliferative effects on SKOV3, MDA-MB-231 and HepG2 cells, with IC50 values of 10.39 μM, 64.48 μM and 4.49 μM, respectively[1].
SYK-IN-15 (2.5-10 μM; 14 days) inhibits the colony formation of SKOV3 cells in a dose-dependent manner[1].
SYK-IN-15 (2.5-10 μM; 24 h) induces dose-dependent S-phase cell cycle arrest in SKOV3 cells[1].
SYK-IN-15 (2.5-10 μM; 24 h) promotes apoptosis of SKOV3 cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SKOV3 cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:14 days
-
Result:Dose-dependently suppressed the clonogenic potential of SKOV3 cells.
-
Cell Line:SKOV3 cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Induced dose-dependent S phase cell cycle arrest in SKOV3 cells.
-
Cell Line:SKOV3 cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Dose-dependently induced apoptosis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6 weeks old, SKOV3 cells subcutaneous xenograft)[1]
-
Dosage:30 mg/kg; 60 mg/kg
-
Administration:p.o.; daily; 21 days
-
Result:Reduced tumor volume to 98.35 mm3 (30 mg/kg group) and 78.51 mm3 (60 mg/kg group), compared to 237.7 mm3 in control group.
Achieved tumor inhibition rates of 58.62% (30 mg/kg group) and 66.97% (60 mg/kg group).
Reduced tumor weight to 83.26 mg (30 mg/kg group) and 53.10 mg (60 mg/kg group), compared to 235.3 mg in control group.
Showed no significant differences in body weight or major organ weights (heart, liver, spleen, lung, kidney) between treated and control groups.
Exhibited no significant organ abnormalities via histopathological analysis.
Chemical Information
-
Molecular Weight 513.64
-
Formula C28H35N9O
-
SMILES
CC(C)OC(C1)CN1C(CC2)CCN2C(C=C3)=C(C)C=C3NC4=NC(C5=NC(N)=CN=C5)=CN6C4=NC=C6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SYK-IN-15 Related Classifications
HY-184306 Related Classifications
Powered by Bioz